LOUISVILLE, Ky. / Oct 09, 2023 / Business Wire / Humana Inc. (NYSE: HUM) will release its financial results for the third quarter 2023 (3Q23) on Wednesday, November 1, 2023, at 6:30 a.m. Eastern time. The company will host a conference call at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2023.
To participate via telephone, please register in advance here.
Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID.
A webcast of the 3Q23 earnings call may also be accessed via Humana’s Investor Relations page at https://humana.gcs-web.com/.
The company suggests participants for both the conference call and those listening via the web dial in or sign on at least 15 minutes in advance of the call. For those unable to participate in the live event, the virtual presentation archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page at https://humana.gcs-web.com/, approximately two hours following the live webcast.
The company’s 3Q23 earnings news release is expected to include financial measures that are not in accordance with Generally Accepted Accounting Principles (GAAP). A reconciliation of non-GAAP financial measures to financial results under GAAP, as well as management’s reasons for including non-GAAP financial measures, will be included in the company’s 3Q23 earnings news release, a copy of which will be available on the Investor Relations page of www.humana.com on November 1, 2023.
About Humana
Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.
Last Trade: | US$293.97 |
Daily Change: | 16.19 5.83 |
Daily Volume: | 2,221,854 |
Market Cap: | US$35.400B |
November 12, 2024 October 30, 2024 October 24, 2024 October 23, 2024 August 19, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB